WO2022149937A3 - 골관절염 치료를 위한 건조된 세포 분비물 기반 치료제 - Google Patents

골관절염 치료를 위한 건조된 세포 분비물 기반 치료제 Download PDF

Info

Publication number
WO2022149937A3
WO2022149937A3 PCT/KR2022/000401 KR2022000401W WO2022149937A3 WO 2022149937 A3 WO2022149937 A3 WO 2022149937A3 KR 2022000401 W KR2022000401 W KR 2022000401W WO 2022149937 A3 WO2022149937 A3 WO 2022149937A3
Authority
WO
WIPO (PCT)
Prior art keywords
culture
solution
derived ingredients
culture solution
crystallized
Prior art date
Application number
PCT/KR2022/000401
Other languages
English (en)
French (fr)
Other versions
WO2022149937A2 (ko
Inventor
황석연
이윤우
고희승
박희정
김정욱
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Priority to EP22736914.7A priority Critical patent/EP4275692A2/en
Priority to US18/271,294 priority patent/US20240066069A1/en
Publication of WO2022149937A2 publication Critical patent/WO2022149937A2/ko
Publication of WO2022149937A3 publication Critical patent/WO2022149937A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dermatology (AREA)

Abstract

본 발명은 PCA(Precipitation with Compressed Fluid Anti-solvent) 건조 공정을 이용한 배양액 유래성분 또는 결정화된 배양액의 제조방법, 상기 방법으로 제조된 배양액 유래성분 또는 결정화된 배양액을 이용하여 연골세포를 회복시키는 방법, 상기 배양액 유래성분 또는 결정화된 배양액을 이용한 연골세포를 회복시키는 방법을 이용하여 골관절염이 발병된 개체를 치료하는 방법, 상기 배양액 유래성분 또는 결정화된 배양액을 이용하여 골관절염이 발병된 개체를 치료하는 방법 및 골관절염 치료를 위한 배양액 유래성분 또는 결정화된 배양액의 용도에 관한 것이다. 본 발명에서 제공하는 배양액 유래성분은 염증성 환경 완화 및 이화작용 관련 유전자 발현 억제활성이 우수하고, 본 발명에서 제공하는 방법을 이용하면, 상기 배양액 유래성분을 보다 높은 수율로 제조할 수 있으므로, 골관절염의 치료제 개발에 널리 활용될 수 있을 것이다.
PCT/KR2022/000401 2021-01-08 2022-01-10 골관절염 치료를 위한 건조된 세포 분비물 기반 치료제 WO2022149937A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP22736914.7A EP4275692A2 (en) 2021-01-08 2022-01-10 Dried-cell-secretome-based therapeutic agent for treating osteoarthritis
US18/271,294 US20240066069A1 (en) 2021-01-08 2022-01-10 Dried cell secretome-based therapeutic agent for osteoarthritis treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210002725 2021-01-08
KR10-2021-0002725 2021-01-08

Publications (2)

Publication Number Publication Date
WO2022149937A2 WO2022149937A2 (ko) 2022-07-14
WO2022149937A3 true WO2022149937A3 (ko) 2022-09-01

Family

ID=82357366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/000401 WO2022149937A2 (ko) 2021-01-08 2022-01-10 골관절염 치료를 위한 건조된 세포 분비물 기반 치료제

Country Status (4)

Country Link
US (1) US20240066069A1 (ko)
EP (1) EP4275692A2 (ko)
KR (1) KR20220100547A (ko)
WO (1) WO2022149937A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003782A2 (en) * 1988-10-05 1990-04-19 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US9138705B2 (en) * 2010-11-22 2015-09-22 Hong Kong Polytechnic University Method for precipitating a solute from a solution
US9259396B2 (en) * 2012-01-20 2016-02-16 Nano And Advanced Materials Institute Limited Method of preparing soy isoflavone nanoparticles by precipitation with compressed antisolvent (PCA) using a supercritical fluid
KR20200106779A (ko) * 2019-03-05 2020-09-15 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2276945C (en) 1993-11-30 2006-08-01 G.D. Searle & Co. Tricyclic-substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions thereof
JP4959916B2 (ja) 2001-08-14 2012-06-27 メディポスト・カンパニー・リミテッド 関節軟骨損傷治療用組成物
KR102154923B1 (ko) 2019-03-05 2020-09-10 서울대학교산학협력단 배양액의 결정화 및 초임계 건조 장치 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003782A2 (en) * 1988-10-05 1990-04-19 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US9138705B2 (en) * 2010-11-22 2015-09-22 Hong Kong Polytechnic University Method for precipitating a solute from a solution
US9259396B2 (en) * 2012-01-20 2016-02-16 Nano And Advanced Materials Institute Limited Method of preparing soy isoflavone nanoparticles by precipitation with compressed antisolvent (PCA) using a supercritical fluid
KR20200106779A (ko) * 2019-03-05 2020-09-15 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUSARO, F. ; KLUGE, J. ; MAZZOTTI, M. ; MUHRER, G.: "Compressed CO"2 antisolvent precipitation of lysozyme", THE JOURNAL OF SUPERCRITICAL FLUIDS, ELSEVIER, AMSTERDAM, NL, vol. 49, no. 1, 1 May 2009 (2009-05-01), AMSTERDAM, NL , pages 79 - 92, XP026048780, ISSN: 0896-8446, DOI: 10.1016/j.supflu.2008.12.005 *

Also Published As

Publication number Publication date
US20240066069A1 (en) 2024-02-29
WO2022149937A2 (ko) 2022-07-14
KR20220100547A (ko) 2022-07-15
EP4275692A9 (en) 2024-03-27
EP4275692A2 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
Jha et al. Microbial L-asparaginase: a review on current scenario and future prospects
BR112019024637A2 (pt) Método para produzir células progenitoras renais, célula progenitora renal, organoide renal, composição farmacêutica, e, agente terapêutico para uma doença renal.
MXPA05011861A (es) Uso de efectores de ciclasas de glutamato y glutaminil.
TW200621980A (en) Anti-glypican 3 antibody having modified sugar chain
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
HRPK20050403B3 (en) Process for preparing 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
AU2017285758A1 (en) Method for improving salt tolerance of plant
UA89067C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
EP3674313A8 (en) Novel polypeptide and method for producing imp using same
MX2022001933A (es) Inhibidores de enzimas.
BR112022014327A2 (pt) Método de cultivo de células humanas, composição de meio de cultura para cultivar células humanas e células humanas
IL165217A (en) Pesticidal pyridinecarboxamide derivatives, process for their preparation, pesticidal compositions comprising them and use thereof in the preparation of pesticidal compositions
Broquist et al. “Citrovorum factor” activity of tetrahydropteroylglutamic acid
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
WO2009072635A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2022149937A3 (ko) 골관절염 치료를 위한 건조된 세포 분비물 기반 치료제
MX2022001080A (es) Metodos y composiciones para reducir la inmunogenicidad mediante inhibidores de celulas b no agotadores.
ATE391730T1 (de) Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
HUP0400213A2 (hu) Deuterált N- és alfa-helyettesített difenil-alkoxi-ecetsav-(amino-alkil)-észterek, valamint az ezen vegyületeket tartalmazó gyógyszerkészítmények
YU86101A (sh) Inhibitori faktora viia
WO2023220131A3 (en) PI3Kα INHIBITORS AND METHODS OF USE THEREOF
MX2023005491A (es) Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas.
MX2023006231A (es) Inhibidores de enzimas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22736914

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022736914

Country of ref document: EP

Effective date: 20230808